disease-modifying antirheumatic drug

(redirected from Antirheumatic agents)
Also found in: Wikipedia.

disease-modifying antirheumatic drug (DMARD)

a classification of antirheumatic agents referring to their ability to modify the course of disease, as opposed to simply treating symptoms such as inflammation and pain. Agents in this group include auranofin, azathioprine, cycloSPORINE, gold salts, hydroxychloroquine, leflunomide, methotrexate, D-penicillamine, and sulfasalazine.

disease-modifying antirheumatic drug

DMARD Rheumatology Any agent–eg, azathioprine, gold, cyclophosphamide, hydroxychloroquin, and MTX–which slows the rate of joint destruction in rheumatoid arthritis

disease-modifying antirheumatic drug

Abbreviation: DMARD
A drug that is used to treat rheumatoid arthritis and acts more slowly but more effectively than nonsteroidal anti-inflammatory drugs. Such drugs include hydroxychloroquine, methotrexate, and tumor necrosis factor inhibitors.
Synonym: slow-acting antirheumatic drug
See also: drug
References in periodicals archive ?
Over the forecast period, the GI market's growth will be determined by the growth of the immunosuppressants and antirheumatic agents.
Purpose of this contract is to obtain anti-inflammatory and antirheumatic agents (M01) and opioids (N02A) of salicylic acid and its derivatives (N02BA) and aniline (N02BE).
Conventional, small molecule, disease-modifying antirheumatic agents (DMARDs) remain the mainstay of early-line treatment, but patients who fail such agents, patients with severe disease, or patients in whom conventional DMARDs are contraindicated are treated with biological DMARDs.
Discover which autoimmune drug classes will provide the greatest franchise growth potential and identify the growth drivers of major treatment classes including immunosuppressants, antirheumatic agents, COX-II inhibitors, NSAIDs and corticosteroids.